2020
DOI: 10.1016/j.clnu.2019.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
38
1
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 48 publications
(47 citation statements)
references
References 26 publications
1
38
1
2
Order By: Relevance
“…However, the presence of albumin is not included in the criteria. Given the present and recent results from Silva et al [33] it is clear that hypoalbuminemia in the presence of a systemic inflammatory response offers readily available additional insight into body composition and the likely outcome of the patient with operable colorectal cancer.…”
Section: Discussionmentioning
confidence: 83%
See 1 more Smart Citation
“…However, the presence of albumin is not included in the criteria. Given the present and recent results from Silva et al [33] it is clear that hypoalbuminemia in the presence of a systemic inflammatory response offers readily available additional insight into body composition and the likely outcome of the patient with operable colorectal cancer.…”
Section: Discussionmentioning
confidence: 83%
“…The combination of C-reactive protein and albumin, termed the Glasgow Prognostic Score (GPS), has been reported to be informative of the nutritional risk of patients with cancer [33] and has been used successfully to predict survival in patients with a variety of common solid tumors, both in the operable [10] and advanced inoperable setting [9]. Therefore, taken together, the literature points to close linkage of nutritional risk and the systemic inflammatory response in patients with cancer and indicates that if one is measured, then the other should be measured also [7].…”
Section: Discussionmentioning
confidence: 99%
“…Cancer cachexia is a multifactorial syndrome characterized by ongoing loss of skeletal muscle mass, malnutrition, and progressive functional impairment [10]. Cancer cachexia is associated with increased treatmentrelated toxicity and poor prognosis in cancer patients [11][12][13]. Given the high tumor burden of DLBCL and the favorable response rate with substantial treatmentrelated toxicities of R-CHOP treatment, the prognostic role of cancer cachexia is also likely to be observed in DLBCL patients.…”
Section: Introductionmentioning
confidence: 99%
“…Of the present criteria considered, it is the only one that is completely objective as it relies on two routine, laboratory-derived values. Indeed, it has been termed "laboratory cachexia" as its values become increasingly abnormal towards death [38] and the mGPS above has been used to define cancer cachexia [39,40]. There are other measures of the systemic inflammatory response that have been shown to have prognostic value, such as the neutrophil lymphocyte ratio which can be collected as part of the routine differential white cell count.…”
Section: Discussionmentioning
confidence: 99%
“…However, such ratios have not been well defined and their relationship with the syndrome of cachexia has not been shown [7,41,42]. With reference to BMI/WL grade it is not clear whether this has additional value to other nutritional risk screening tools such as the Malnutrition Universal Screening Tool (MUST) and the Patient Generated Subjective Global Assessment (PG-SGA) that are in routine clinical use [36,40]. Therefore, further comparative studies are required to establish the value of BMI/WL grade as a measure of cachexia in patients with advanced cancer.…”
Section: Discussionmentioning
confidence: 99%